Andersson A, Persson P M, Fredrikson S
Avdelning för biofarmaci, Uppsala universitet.
Lakartidningen. 1999 Dec 8;96(49):5492-5.
Interferon-beta (IFNB) is the first agent to be registered in Sweden for modifying disease course in multiple sclerosis (MS). A nationwide survey uncovered a tenfold variation between counties in the prescribing of IFNB. About 10% of patients received treatment in a few counties, while in most the figure was even smaller. No correlation was found between sales of IFNB and numbers of neurologists in the respective counties. Patients should receive treatment according to national medical guidelines, regardless of place of residence.
β-干扰素（IFNB）是瑞典首个获批用于改变多发性硬化症（MS）病程的药物。一项全国性调查发现，各县在IFNB处方量上存在10倍的差异。在少数几个县，约10%的患者接受了治疗，而在大多数县，这一比例甚至更低。未发现各县IFNB的销售量与神经科医生数量之间存在相关性。无论居住在何处，患者都应根据国家医学指南接受治疗。
